Financial Performance - The company reported a net loss of $11.0 million for the three months ended March 31, 2024[113]. - For the three months ended March 31, 2024, the company reported revenues of $14,000, a decrease of 63.16% from $38,000 in the same period of 2023[127]. - The net loss for the three months ended March 31, 2024, was $11.0 million, compared to a net loss of $6.5 million for the same period in 2023, representing an increase of 68.5%[133]. - Total operating expenses for the three months ended March 31, 2024, were $11.0 million, an increase of 70.8% from $6.5 million in the same period of 2023[126]. - The company used approximately $7.5 million in cash for operating activities during the three months ended March 31, 2024, compared to $1.1 million in the same period of 2023[145]. - Cash and cash equivalents decreased to $26.0 million as of March 31, 2024, down from $51.0 million at the end of the same period in 2023[143]. - As of March 31, 2024, the company had cash and cash equivalents of $26.0 million, down from $35.8 million as of December 31, 2023[113]. - The company has incurred losses in each period since inception, raising substantial doubt about its ability to continue as a going concern[114]. Research and Development - The company plans to initiate a Phase II trial for Alzheimer's disease (AD) with 201 patients enrolled in a 2:1 ratio (XPro vs placebo)[108]. - In the Phase I trial for AD, XPro demonstrated a decrease in inflammatory cytokines in the cerebrospinal fluid (CSF) by 84% for neurofilament light chain, 46% for phospho Tau 217, and 91% for VILIP-1 after three months of therapy[107]. - The company received a $2.9 million award from the National Institute of Mental Health (NIMH) to treat treatment-resistant depression (TRD) with XPro[110]. - The Phase I/II trial using INKmune for metastatic castrate-resistant prostate cancer (mCPRC) is expected to be fully enrolled by the first half of 2025, with top-line data available six months later[112]. - The company anticipates significant increases in research and development expenses as it advances more product candidates through clinical development[123]. - Research and development expenses increased to approximately $8.7 million for the three months ended March 31, 2024, compared to $4.1 million for the same period in 2023, reflecting a 111.4% increase[129]. Financing Activities - The company sold 198,364 shares of common stock at an average price of $10.56 for gross proceeds of approximately $2.1 million under the ATM offering from April 4, 2024, to May 6, 2024[134]. - The company raised approximately $4.8 million from the sale of 571,592 shares of common stock and warrants on April 19, 2024[135]. - The company raised approximately $9.7 million from the sale of 986,000 shares of common stock and warrants on April 24, 2024[136]. - The Company repaid $2.5 million of its debt during the three months ended March 31, 2024[147]. Regulatory and Compliance - The company qualifies as an "emerging growth company" under the JOBS Act, allowing for reduced disclosure requirements[115]. - The Company is classified as a "smaller reporting company" and is not required to provide certain market risk disclosures[150]. - There have been no material changes in critical accounting policies and estimates during the three months ended March 31, 2024[148]. Future Plans - The company plans to apply for an accelerated pathway for XPro in 2024, potentially qualifying for Fast Track status[109]. - The company has completed an open-label dose escalation trial for INB03 in cancer patients with metastatic solid tumors, demonstrating safety and pharmacodynamic endpoints[106].

Boca Raton, Florida, April 25, 2024 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announced today that it has entered into definitive agreements for the sale and purchase of 986,000 shares of its common stock and warrants to purchase up to an aggregate of 986,000 shares of its common stock at an offering price of $9.84 per share of common stock a ...

Boca Raton, Florida, April 23, 2024 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, is delighted to announce the successful completion of the extended stability validation for XProTM continuous storage in solution at 2-8C. The 24 and 30-month stability test samples passed all chemistry and potency assays; allowing the Company to make a conservative claim ...

picturegarden/DigitalVision via Getty Images Topline Summary and Update INmune Bio (NASDAQ:INMB) is a company focused on developing drugs in two different disease areas: neurology and cancer medicine. I've previously covered this company in two articles, and I was a cautious optimist in my latest outing, with main reservations related to their cash burn rate and the challenges of developing drugs for Alzheimer disease, which is their most advanced focus. This article is an update providing a picture of ...

Exhibit 99.1 INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update Company to Host Conference Call Today, March 28, at 4:30pm ET BOCA RATON, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical- stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the year ended December 31, 2023 and provides a business update. Q4 2023 and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-38793 INMUNE BIO INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38793 INMUNE BIO INC. (Exact name of registrant as specified in its charter) (Address of principal executive of ice) (Zip code) (858) 964-3720 (Registrant's ...

INmune Bio, Inc. (NASDAQ:INMB) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants David Moss - Chief Financial Officer RJ Tesi - Chief Executive Officer & Chief Medical Officer Conference Call Participants Joel Beatty - Baird Operator Greetings, and welcome to the INmune Bio Second Quarter 2023 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. A transcript will follow within 24 hours of this conference call. At this time, it is my pleasure ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 INMUNE BIO INC. (Exact name of registrant as specified in its charter) (State of incorporation) (I.R.S. Employer Nevada 47-5205835 Identification No.) | Large accelerated filer | ☐ | Acceler ...

INmune Bio, Inc. (NASDAQ:INMB) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants David Moss - Chief Financial Officer RJ Tesi - Chief Executive Officer Mark Lowdell - Chief Scientific Officer Conference Call Participants Tom Shrader - BTIG Daniel Carlson - Tailwinds Research Operator Good day and welcome to the INmune Bio First Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] Please note today's event is being recorded. ...